Clinical Benefit and Safety of Combined Immunotherapy and Targeted Therapy in Prostate Cancer.

Int J CancerApr 22, 2026 (epub)
Clinical ResearchOncology (Medical)Open access

Zeyu Han, Xianyanling Yi, Yaxiong Tang et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis evaluated the efficacy and safety of combined immunotherapy and targeted therapy in prostate cancer, involving 5702 participants across 21 studies. The findings indicate that combination therapy significantly improved disease control rate (RR = 1.42), complete response (RR = 2.56), and partial response (RR = 2.13), though with increased adverse events.

Key findings

  • Combination therapy improved disease control rate (RR = 1.42) compared to monotherapy.
  • Complete response was significantly higher with combination therapy (RR = 2.56).
  • Partial response increased with combination therapy (RR = 2.13).
  • Median overall survival was 16.79 months in the combined treatment group.

Why it matters

The study highlights the potential of combining immunotherapy with targeted therapy to enhance treatment outcomes in prostate cancer, which may influence future therapeutic strategies and clinical decision-making.

Source

PubMed · PMID 42017392Free full text on PubMed Central

Published in Int J Cancer. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchVascular SurgeryOpen access

Revascularization of Asymptomatic Carotid Artery Stenosis: Cognitive Results of the CREST-2 Randomized Trials.

This prespecified cognitive-outcomes analysis of the multicentre, randomised CREST-2 trials assessed patients aged 35 years or older with at least 70% asymptomatic carotid stenosis.

JAMAOct 27, 2026Read summary
Clinical ResearchObstetrics & GynecologyOpen access

Intrauterine Mepivacaine Instillation vs Placebo for Pain During IUD Placement: A Randomized Clinical Trial.

This multicentre, double-blind, randomised, placebo-controlled trial tested intrauterine mepivacaine before IUD placement in nulliparous individuals aged 18 to 31 years at 11 Swedish clinics.

JAMAOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.